On February 22, 2023 Ordaōs, a biotechnology company designing novel mini-proteins to help drug hunters deliver life-saving treatments, reported a collaboration with FatiAbGen, a South Korea-based biopharma company developing monoclonal antibody-based therapies (Press release, Ordaōs Bio, FEB 22, 2023, View Source [SID1234627549]). As a part of their partnership, Ordaōs will use their in silico Design Engine to optimize antibodies for several oncology conditions including pancreatic and ovarian cancer, of which there is a high unmet need.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Ordaōs is pleased to be collaborating with FatiAbGen to optimize their monoclonal antibodies for the treatment of these debilitating cancers," said Ziwei Liang, CSO of Ordaōs. "Together in partnership, we can address many of the challenges faced in difficult-to-treat diseases and help develop therapeutics for those patients who currently have limited options."
As part of this collaboration, Ordaōs will employ their proprietary in silico Design Engine to optimize the overall safety and efficacy of FatiAbGen’s existing monoclonnal anitbodies. The Ordaōs Design Engine, which leverages the power of multitask, metalearning AI, can rapidly enhance FatiAbGen’s existing antibodies indicated for a number of oncology conditions. FatiAbGen will then be responsible for developing these antibodies in pre-clinical study.
"We remain committed to meeting the unmet needs of patients by exploring new and challenging technologies and markets," Said JayJay Lee, CEO of FatiAbGen. "Combining our capabilities with Ordaōs and their proprietary Design Engine will further our efforts in creative research, development and delivery to patients in need of a treatment."
FatiAbGen will utilize their capabilities in manufacturing antibodies in therapeutic markets in tandem with their fusion protein antibody drug conjugate(ADC) platform technology. FatiAbGen currently has developed novel antibodies for treating autoimmune diseases that cause allergies, and has previously used their proprietary technology to develop treatments for Mesothelioma and pancreatic cancer.
To learn more, visit the Ordaōs website, or email [email protected].